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ABSTRACT
Sublingual immunotherapy (SLIT) with house dust mite (HDM) preparation has been shown to reduce disease severity in patients 
with atopic dermatitis (AD). A 5-year-old girl with severe Atopic Dermatitis refractive to all possible pharmacotherapy was put on 
SLIT for dust mite and followed up for a period of one year. SLIT to dust mite proved highly effective in reducing the disease severity 
score as well as prevention of exacerbations in this patient.
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Aeroallergens, especially house dust mite (HDM) or food allergens, play a relevant role in aggravating the eczematous skin lesions and may contribute to the flare-
ups of eczema in those patients [1,2,3,4]. About 80% of the patients 
with atopic dermatitis (AD) have an IgE sensitization toward foods 
or environmental allergens. Among the most important etiological 
factors in AD development are allergens of house dust mites and 
their waste products (HDMA). Due to high enzymatic activity, 
HDMA are able to penetrate through the damaged epidermal skin 
barrier of patients with AD to get the access to immune cells.
HDMA cause allergic response both of immediate and delayed 
types that lead to worsening of AD [5]. Double-blind controlled 
research has proved the role of HDMA in children and adults’ AD 
initiation [6]. The complexity of AD warrants the use of several 
different therapeutic approaches although a truly curative therapy still 
does not exist [7]. It is well known that specific immunotherapy (SIT) 
is highly effective in IgE mediated allergic diseases [8]. SIT modifies 
at the earliest steps the immune response to allergens [9]; thereby 
validating the role of SIT in the management of atopic dermatitis. 
CASE REPORT
A 5-year-old girl childpresented at the Allergic Clinic, 
Department of Immunology, Srinagar with complaints of 
severe refractory atopic dermatitis with multiple lesions all 
over her body especially hands, feet, scalp and trunk. The 
young girl had been on full-fledged pharmacotherapy since 3 
years; which included local steroids, moisturizers, emollients 
and antibiotics as well as systemic steroids, antihistamines, 
immunosuppressants (Methotrexate, cyclosporine, etc). The 
patient had been seen by multiple specialities and was referred 
to us by a dermatologist.
On general examination, her weight was 20 kg and height 
was 106 cm, with a puffy face and was nervous, ill-appearing 
and fidgety.Her vitals like temperature, heart rate, respiratory 
rate and blood pressure were within normal limits.The patient 
was found to have profusely oozing lesions all over the body, 
especially scalp, upper limbs, feet and lower back. The SCORAD 
(SCORing Atopic Dermatitis) score of the patient was calculated 
to be 98.3 (Fig.1). The patient had developed cushingoid features 
probably because of 3 years of unabated steroid use. 
Her total IgE level was 3500 IU/ml and eosinophil count 
was 12.5%. Swab culture showed Methicillin-Resistant 
Staphylococcus aureus (MRSA), sensitive to Linezolid and 
Vancomycin. Skin Prick Test, to identify sensitization to various 
allergens was not possible because of her eczematous lesions; 
instead In vitro testing for specific IgEs to eczema panel was done, 
which showed highly sensitive to dust mite (> 100 IU), moderate/
mild sensitivity to cockroach and some foods and negative to all 
other aeroallergens, indicating sensitization to HDM as a trigger 
for Atopic Dermatitis exacerbations.
Our line of treatment began with the withdrawal of high dose 
systemic steroids as well as immunosuppressants while continuing 
the patient on antihistaminics. Subsequently, an endocrinology 
consultation was made for where she was put on minimum dose 
hydrocortisone, in view of the suppressed hypothalamic pituitary 
adrenal (HPA) axis. Oral Linezolid was prescribed for MRSA 
infection.Topical pharmacotherapy, which includedantibiotics, 
steroids and calcineurin inhibitors were continued. The use of 
wet wraps and other hydration therapies was also well explained 
to her attendants. 
Allergen avoidance measures for dust mite were instituted 
which included dust mite free bedding, upholstery and furnishing.
Other lifestyle modifications(avoiding humid and high-
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temperature environment) were also explained to prevent flare-
ups. Sublingual Immunotherapy (SLIT) to dust mite for sustained 
recovery was started. The SLIT consisted of 43 µg of allergen 
extract per tablet (2800 Biological Active Units) administered 
twice a day for a period of one year, to be continued for a period 
of three years.
We observed a significant improvement in the eczematous 
lesions after completing one year of Sublingual Immunotherapy 
(SLIT). SCORAD Score decreased significantly from 98.3 to 
32.4 at 6 months and further decreased to 18.5 at the end of 
one year of immunotherapy. We also observed a significant 
regression of Cushingoid features one year after starting 
immunotherapy and reducing the steroids to a minimal possible 
level (Figure 2 and 3).
DISCUSSION
AD is frequently the first clinical manifestation of atopic disease 
in infancy [10]. Although basic management includes optimal 
skin care, emollient creams, topical corticosteroids and/or topical 
calcineurin inhibitors, SIT is the only disease-specific treatment 
modality that suppresses allergic responses for a long period of time. 
Dermatophagoides farina (Der f), Dermatophagoides pteronyssinus 
(Der p) and Blomia are the most common types of HDM. The 
antigenically active particles contain high enzymatic activity which 
destroys tight junction of the epidermis, enhancing penetration of 
allergens deep into the skin [11]. One of these HDM enzymes is serine 
cysteine proteinase which is able to activate proteinase-activated 
receptors (PARs). These PARs are known to be most populated in 
Figure1: (a and b) Lesions before immunotherapy; (c) Cushingoid features due to prolonged steroid use.
Figure 2:(a and b) Improvement in lesions after 6 months of immunotherapy; (c) Regression of Cushingoid features after 6 months of 
immunotherapy.
Vol 5 | Issue 2 | Mar - Apr 2019 Indian J Case Reports    125
Rasool et al.  Sublingual immunotherapy to house dust mite as an immunological intervention
respiratory, gastrointestinal systems and skin [12]. When PAR is 
activated, various inflammatory mediators such as IL-6 and IL-8 
are secreted, leading to increase in vascular permeability, infiltration 
of leukocytes, increased airway hypersensitivity, and other effects 
by HDM that preceded clinical symptoms of allergic diseases [13]. 
SIT aims to induce allergen-specific tolerance through acquiring 
immune tolerance with induction of allergen-specific regulatory 
T cells (Tregs)[14]. These observations have been validated by a 
recent study which has shown that SCIT with HDM allergen is 
effective in reducing the SCORAD index and reducing the need for 
topical corticosteroids [15].
CONCLUSION
The use of sublingual immunotherapy in this patient ensured 
100% compliance with minimal side effects or adverse reactions. 
There were only mild flares during this first year, which were 
effectively managed by topical steroids. The quality of life 
improved very significantly in this patient and complete 
regression of all the symptoms is expected to occur after the 
patient completes three years of immunotherapy.These results 
suggest that allergen-specific immunotherapy could be a relevant 
therapeutic option in the management of AD.
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Figure 3: (a and b) Complete resolution of lesions after 1 year of immunotherapy; (c) Complete regression of Cushingoid features.
